SG Americas Securities LLC Buys New Stake in RXi Pharmaceuticals Corp (RXII)

Share on StockTwits

SG Americas Securities LLC bought a new stake in shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 118,387 shares of the biotechnology company’s stock, valued at approximately $228,000.

RXII has been the subject of several recent research reports. HC Wainwright set a $3.00 target price on shares of RXi Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 15th. ValuEngine upgraded shares of RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd.

RXII opened at $1.19 on Wednesday. The company has a market capitalization of $5.25 million, a price-to-earnings ratio of -0.28 and a beta of 1.29. RXi Pharmaceuticals Corp has a 1-year low of $1.12 and a 1-year high of $7.70.

RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.16. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.02 million. sell-side analysts anticipate that RXi Pharmaceuticals Corp will post -2.14 EPS for the current year.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Featured Story: Dividend Aristocrat Index

Want to see what other hedge funds are holding RXII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RXi Pharmaceuticals Corp (NASDAQ:RXII).

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

SG Americas Securities LLC Buys New Stake in RXi Pharmaceuticals Corp
SG Americas Securities LLC Buys New Stake in RXi Pharmaceuticals Corp
Graco Inc.  Holdings Reduced by Renaissance Technologies LLC
Graco Inc. Holdings Reduced by Renaissance Technologies LLC
Renaissance Technologies LLC Boosts Holdings in Urstadt Biddle Properties Inc
Renaissance Technologies LLC Boosts Holdings in Urstadt Biddle Properties Inc
GCP Applied Technologies Inc  Stake Increased by Russell Investments Group Ltd.
GCP Applied Technologies Inc Stake Increased by Russell Investments Group Ltd.
Cardtronics PLC  Shares Sold by Schwab Charles Investment Management Inc.
Cardtronics PLC Shares Sold by Schwab Charles Investment Management Inc.
Robert Half International  Downgraded to “Hold” at Zacks Investment Research
Robert Half International Downgraded to “Hold” at Zacks Investment Research


Leave a Reply

 
© 2006-2018 Zolmax.